RedHill Biopharma vs XTL Biopharmaceuticals
RDHL and XTLB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RDHL | XTLB |
|---|---|---|
| Size and price | ||
| Share price | $0.375 | $1.60 |
| Change, 1 year | −65.0% | −58.8% |
| Change, 5 years | −100.0% | −87.9% |
| Beta (5Y) | 1.71 | 0.98 |
| Employees | 13 | 3 |
| StockData Score | ||
| Total score | 0 | 0 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −96.4% | – |
| Revenue growth, 5Y average | −66.2% | – |
| Profitability | ||
| Operating margin | −2777% | – |
| FCF margin | −3376% | – |
| Financial health | ||
| Interest coverage | −5.5× (better) | −6.3× |
| Current ratio | 0.34 | – |
| Ownership | ||
| Held by institutions | 0.00% | 0.00% |
| Held by insiders | 4.4% | 0.00% |
| Insider net buying, 12 months | −$1.4K | – |
Go deeper
- RDHL stock overview
- RDHL income statement
- RDHL valuation and score
- XTLB stock overview
- XTLB income statement
- XTLB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.